Transforming Antibody Therapy
People
Latest news
19 Dec, 2024
Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results for SOR102 in Ulcerative Colitis
19 Dec, 2024
Exclusive: Can oral antibodies work? A small startup thinks it has an answer
3 Sep, 2024
Sorriso Pharmaceuticals Completes Enrollment in Phase 1b Clinical Trial of Patients with Ulcerative Colitis
17 May, 2024
Sorriso Pharmaceuticals Announces First Patients Dosed in Phase 1b Clinical Trial for Patients with Ulcerative Colitis
1 Nov, 2023
Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
22 Dec, 2021
Sorriso Pharmaceuticals Launches with $31 Million to Develop Novel Class of Orally Delivered Cytokine Antibodies to Treat Inflammatory Conditions